F M Investments LLC Acquires New Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

F M Investments LLC acquired a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 31,313 shares of the biotechnology company's stock, valued at approximately $2,731,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Blueprint Medicines by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock worth $590,905,000 after buying an additional 91,450 shares during the last quarter. Wellington Management Group LLP increased its stake in Blueprint Medicines by 8.0% in the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock valued at $373,421,000 after acquiring an additional 316,754 shares during the last quarter. State Street Corp raised its position in Blueprint Medicines by 16.2% during the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock valued at $255,827,000 after purchasing an additional 385,818 shares in the last quarter. William Blair Investment Management LLC raised its position in Blueprint Medicines by 16.1% during the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock valued at $169,616,000 after purchasing an additional 269,896 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Blueprint Medicines by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,490,101 shares of the biotechnology company's stock worth $129,996,000 after purchasing an additional 9,914 shares during the last quarter.

Remove Ads

Analyst Ratings Changes

BPMC has been the topic of a number of research reports. Morgan Stanley started coverage on Blueprint Medicines in a report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price objective on the stock. Stephens restated an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a report on Thursday, January 2nd. Needham & Company LLC reaffirmed a "buy" rating and set a $133.00 target price on shares of Blueprint Medicines in a report on Tuesday, April 8th. Jefferies Financial Group assumed coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They issued a "buy" rating and a $135.00 price target for the company. Finally, Scotiabank initiated coverage on Blueprint Medicines in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $124.95.

Insiders Place Their Bets

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares of the company's stock, valued at approximately $6,581,655.32. This trade represents a 3.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the sale, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,358 shares of company stock valued at $2,583,187. 4.21% of the stock is currently owned by corporate insiders.

Blueprint Medicines Stock Down 1.3 %

Blueprint Medicines stock traded down $1.08 on Tuesday, hitting $81.45. 1,175,757 shares of the stock traded hands, compared to its average volume of 766,310. The business's fifty day simple moving average is $90.36 and its 200 day simple moving average is $93.47. The firm has a market cap of $5.21 billion, a P/E ratio of -75.42 and a beta of 0.75. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.